Big pharma, Partnering

Arrowhead acquires Novartis RNAi R&D portfolio

Posted on 09 March 2015

Tags: , , ,

Arrowhead Research announced the acquisition of Novartis' entire RNAi research and development portfolio and associated assets.

The acquisition includes assignment of certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, an exclusive license in the RNAi field to other patents and patent applications owned or controlled by Novartis, assignment of a third party license, three pre-clinical RNAi candidates, and other related assets.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Key aspects of the acquisition include the following:

Multiple patent families covering RNAi-trigger design rules and modifications that fall outside of key patents controlled by competitors, which the Company believes provides freedom to operate for any target and indication;

Novel intracellular targeting ligands that enhance the activity of RNAi-triggers by targeting the RNA-induced silencing complex (RISC) more effectively and improving stability once RISC is loaded;

An assignment of Novartis' license from Alnylam Pharmaceuticals granting Arrowhead access to Alnylam intellectual property, excluding delivery, for 30 gene targets chosen by Novartis;

A pipeline of three candidates initiated by Novartis and for which Novartis has developed varying amounts of preclinical data.

Arrowhead previously made a payment to Novartis of $7 million in cash and will provide an additional payment of $3 million in cash and $25 million in Arrowhead common stock within 30 days.

Novartis is also eligible to receive milestones and single digit royalties on sales of future products in connection with the agreement.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply